Tobias D.
- Country
- Germany
- Department
- Onkologische Praxis
Research Overview
- Phase III Randomized Open-Label Study of Regorafenib and Nivolumab Versus Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer
- Phase III Randomized Study of Datopotamab Deruxtecan and Rilvegostomig Versus Pembrolizumab in Advanced Non-Squamous NSCLC with High PD-L1 Expression
- Phase III Randomized Double-Blind Trial of Tiragolumab and Atezolizumab Versus Placebo and Atezolizumab in Resected Stage IIB-IIIB PD-L1 Positive NSCLC
Data & Insights
Has run more than one trial at 206 of 494 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating gastroesophageal cancers and colorectal malignancies, with particular focus on advanced treatment approaches.
- Gastric and Gastroesophageal Junction Adenocarcinoma
- Metastatic Colorectal Cancer
- Locally Advanced Rectal Cancer
Clinical expertise extends to perioperative treatment strategies and targeted therapeutic combinations for gastrointestinal cancers.
Thoracic Oncology
Focus on innovative treatments for non-small cell lung cancer (NSCLC), particularly addressing advanced and metastatic disease states.
- Advanced Non-Squamous NSCLC
- PD-L1 Expression Positive Lung Cancer
- Immunotherapy Combinations
Expertise in developing treatment strategies incorporating novel immunotherapeutic approaches for lung cancer.
Hematologic Oncology
Research interest in follicular lymphoma treatment, exploring innovative therapeutic combinations.
- Previously Untreated Follicular Lymphoma
- Targeted Therapy Approaches
- Immunotherapy Applications
Focuses on developing treatment strategies for hematologic malignancies using novel therapeutic agents.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.